Addex Therapeutics (ADXN)
(Delayed Data from NSDQ)
$8.13 USD
+0.03 (0.37%)
Updated Aug 4, 2025 10:00 AM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ADXN 8.13 +0.03(0.37%)
Will ADXN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ADXN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADXN
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?
ADXN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
Other News for ADXN
Addex Therapeutics (ADXN) Invests in Stalicla's Autism Drug Development
Stalicla secures CHF 2M investment led by Addex for neuropsychiatric drug development
Addex Therapeutics Secures Shareholder Approval at 2025 AGM
Trading Resumes for Addex Therapeutics (ADXN) | ADXN Stock News
Addex Therapeutics Ltd – ADR trading resumes